Loading clinical trials...
Loading clinical trials...
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06364917 · Non Small Cell Lung Cancer
NCT05076760 · Solid Tumor, Advanced Cancer, and more
NCT07169708 · Non Small Cell Lung Cancer NSCLC
NCT06312137 · Non Small Cell Lung Cancer
NCT07563205 · Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, and more
Novartis Investigative Site
Camperdown, New South Wales
Novartis Investigative Site
Melbourne, Victoria
Novartis Investigative Site
Leuven
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions